Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma

The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Myeloma Behavior Blood Protein Disorders Cardiovascular Diseases Criminal Behavior Dangerous Behavior Driving Under the Influence Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Policlinico S.Orsola Malpighi

Bologna, 40138, Italy

Location status: Recruiting

Location contact

CRISTINA NANNI, MD

CONTACT

[email protected]

+390512143182

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase

Patients who have signed the informed consent form

Exclusion criteria

Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years

Age < 18 years
Women who are breastfeeding or pregnant
Patients with metal implants or devices that constitute an absolute contraindication for MRI
Patients with severe claustrophobia
Patients with bone pain that prevents prolonged maintenance of the supine position

Treatment and study plan

Primary outcomes

positivity rate

Time frame: 33 months

comparison per patient and per lesion between FDG PET CT and WB DWI

Study contacts

Contact information is provided by the study sponsor or research team.

CRISTINA NANNI, MD

CONTACT

[email protected]

+390512143182

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Whole Body DWI Sequences As Compared with Standard FDG PET/CT in Patients with Simptomatic Multiple Myeloma

Acronym: MMR-PET-22-04

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2027
First posted: Oct 26, 2024
Registry last updated: Oct 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting